+

WO1997004750A2 - Process for preparing solid dosage forms of very low-dose drugs - Google Patents

Process for preparing solid dosage forms of very low-dose drugs Download PDF

Info

Publication number
WO1997004750A2
WO1997004750A2 PCT/EP1996/003326 EP9603326W WO9704750A2 WO 1997004750 A2 WO1997004750 A2 WO 1997004750A2 EP 9603326 W EP9603326 W EP 9603326W WO 9704750 A2 WO9704750 A2 WO 9704750A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
drug
carrier
daily dose
pharmaceutical composition
Prior art date
Application number
PCT/EP1996/003326
Other languages
French (fr)
Other versions
WO1997004750A3 (en
Inventor
James Albert Napper
Neil Mortimer
Karen Triona O'brien
Sultan James Manek
Rajinder Kumar
Michael Sidney George Clark
Julia Mary Loudon
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515624.6A external-priority patent/GB9515624D0/en
Priority claimed from GBGB9606684.0A external-priority patent/GB9606684D0/en
Priority to APAP/P/1998/001170A priority Critical patent/AP858A/en
Priority to EP96927621A priority patent/EP0841902A2/en
Priority to SK110-98A priority patent/SK11098A3/en
Priority to EA199800179A priority patent/EA000740B1/en
Priority to IL12289796A priority patent/IL122897A0/en
Priority to EA199901055A priority patent/EA199901055A1/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to NZ315632A priority patent/NZ315632A/en
Priority to BR9609804A priority patent/BR9609804A/en
Priority to MX9800809A priority patent/MX9800809A/en
Priority to JP9507243A priority patent/JPH11510493A/en
Priority to AU67384/96A priority patent/AU716961B2/en
Priority to IL14957996A priority patent/IL149579A0/en
Publication of WO1997004750A2 publication Critical patent/WO1997004750A2/en
Publication of WO1997004750A3 publication Critical patent/WO1997004750A3/en
Priority to NO980384A priority patent/NO980384L/en
Priority to BG102266A priority patent/BG102266A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • This invention relates to a method of formulating solid dosage forms of drugs and to solid dosage forms produced thereby, in particular solid dosage forms containing low dose of drug.
  • the invention also relates to a method of treatment and/or prophylaxis of dementia and unit dosage forms useful therein.
  • the usual challenge in manufacturing solid dosage forms of very low-dose drugs for example with active doses around 5-125 microgramme ( ⁇ g) (for example 0.004-0.1% by weight of drug to total solid), is to ensure homogeneity.
  • the techmcal problem is how to distribute the drug substance evenly among the large amount of excipient particles.
  • Very fine particles of the drug are first mixed with a small portion of excipient; the product then mixed with a slighty larger portion of excipient and so on until the desired mix is obtained.
  • This method relies on the fine drug particles adhering electrostatically to the larger excipient ones, thus preventing segregation.
  • the method works with some drugs, but success depends on the surface properties of both drug and excipient, and the method is very laborious.
  • EP0503521 describes the application of this method to steroidal drugs with high binding affinity and low demixing potential for certain excipients.
  • a preferred alternative method for formulating low dose drugs is known as "wet granulation".
  • the drug is dissolved in water or another solvent, and blended with excipients including a binder, for example povidone, to form a wet mass containing 5-20% by weight of solution to total weight of granulation mix, which is then dried off in a separate step.
  • the binder causes particles of excipient to clump together, and as the mass dries these clumps ("granules”) either contain or are coated with the drug. This is effective but cumbersome since the drying step requires special equipment, and generally involves high temperatures which may degrade labile drugs.
  • the use of the binder requires the further inclusion of a disintegrant such as sodium starch glycolate or starch to help the tablet, which is cohesive, to disperse in the stomach.
  • Fluid bed granulation has been used to achieve content uniformity of low dose (l ⁇ g-lOmg) tablets (Thiel et al., J. Pharm. Pharmacol. 1986, 38, 335-343).
  • the micronised drug is blended as a powder with other excipients, then loaded into a fluid bed granulator, and the powders are agglomerated by spraying on a solution of a binder; drying takes place concomitantly.
  • the process does not require a separate drying step, but it does require the use of micronised drug, and also incorporates a separate blending step prior to granulation. It also requires specialised equipment and precise optimisation ofthe process parameters.
  • carrier granulation Another process for formulating low dose drugs is known as carrier granulation (Michoel et aL, Pharmaceutical Technology June 1988, 66-84). This functions by spraying a solution of binder such as povidone in water onto relatively large excipient particles such as hydrous lactose and then spraying small dry drug substance particles onto that, thus coating the excipient with drug particles which are stuck on by the binder.
  • the quantity of solution used was 3.3-3.5% by weight of solution to total granulation mix.
  • the method was applied to a formulation containing 4-5% drug by weight This method also requires drying; the drug particle size needs to be very small, which often requires an extra milling step and the very fine drug powder may not flow at all well; and the formula still requires a disintegrant
  • Dahl et al., Drug Development and Industrial Pharmacy 1990, 16 (12), 1881-1891 describes the preparation of solid capsule formulations using a spray-on liquid drug carrier.
  • the model drug is dissolved in a non- volatile solvent propylene carbonate, and sprayed onto a compressible sugar at a loading of around 0.01% by weight of drug to total solid, to give a final unit dose of 35 ⁇ g.
  • the solvent being non-volatile remains in the blend. It is added at around 5% by weight of the total formulation; lower ratios of solvent to solid resulted in decreased ability to disintegrate and dissolve.
  • the resulting, somewhat sticky, powder showed some difficulties in automated encapsulation machines, and would be likely to give significant problems in tabletting.
  • Yalkowski (US4,489,026) describes a process which involves very slowly spraying a dilute solution of drug in a volatile inert solvent preferably an organic solvent having a boiling point lower than 80°C, onto excipient powder in an open coating pan; a continuous flow of air dries the product during the spraying process.
  • This process was applied to drugs with a unit dose of lOug or less.
  • the spray rate is limited to 1-lOml/min, making the process suitable only for very small batch-sizes (the example quoted prepared 1000 tablets).
  • the weight ratio of solution to carrier used was 15%; also, the use of volatile organic liquids is now regarded as a significant hazard, requiring solvent-recovery processes and explosion-proof equipment
  • Katdare (US4,898,736) describes a simplified version of this process, suitable for unit doses of 50-1000 ⁇ g; the drug, dissolved in an easily evaporated solvent such as ethanol, methanol, acetone or tetrahydrofuran, is simply blended with excipients in a ratio of 2.26% or 6.75% and then dried, followed by lubrication and tabletting.
  • This process is in principle suitable for commercial scale manufacture, but does still have the problems associated with the use of volatile organic solvents.
  • a drug formulation process which comprises admixing carrier particles with a solution of drug in water in a quantity of 1-3% by weight of solution to total mix.
  • the resulting mixture may be formulated into suitable unit dose presentation, for example by tabletting and optionally film coating the tablets or by encapsulation.
  • the separate blending step aids drying by the dilution effect that is, the residual water is distributed through a greater quantity of carrier powder, and by the longer mixing time.
  • the dilution is conveniently in the range 4/1 to 40/1 carrier/concentrate by weight depending upon the processing characteristics of the carrier.
  • a convenient dilution ratio for lactose monohydrate is 10/1.
  • the solution/mix weight ratio is more preferably up to 2% by weight
  • the optimum quantity of solution will depend upon the absorbent qualities of the carrier particles, the solubility of the drug and the characteristics of the mixing device, the quantity of solution being chosen so as to allow even distribution of drug while avoiding the need for a heated drying step.
  • the mixing step is preferably carried out in a high shear mixer.
  • the carrier may be any suitable soluble, directly compressible pharmaceutically acceptable excipient such as anhydrous lactose, lactose monohydrate, mannitol, or an insoluble, directly compressible pharmaceutically acceptable excipient such as microcrystalline cellulose or dicalcium phosphate, preferably a soluble excipient
  • Any drug having a sufficient degree of solubility in water may be formulated by the process of the invention.
  • the concentration of drug in the soluuon is dependent on the unit dose of drug required, the upper limit being dependent on the solubility ofthe drug.
  • the carrier particles are evenly coated with a very thin film of drug solution. Some of the water naturally dries off during the mixing since there is normally a small airflow through the mixer; the remaining amount is so low that drying is not specifically required. If the tablets are film-coated, a degree of further drying may be obtained during the coating process.
  • the process of the invention has a number of advantages: - it does not require any milling of the drug substance - there is no need for a drying step. This simplifies processing and reduces production costs; heat labile drugs do not suffer at the temperature required for drying; for drugs which are highly potent the omission of the drying step makes it easier to contain dust r improving safety for the factory worker
  • Optional additives in the final mix include a disintegrant; a range of acidic or alkaline excipients to improve chemical stability of the drug in the formulation such as sodium dihydrogen citrate, preferably included in the initial mix; a lubricant such as magnesium stearate; and a glidant such as colloidal silica.
  • the present invention further provides a pharmaceutical composition comprising a drug formulated in accordance with the process of the invention and the use of said composition as an active therapeutic substance.
  • the invention additionally provides a pharmaceutical composition comprising a drug, obtainable by the process of the invention and the use of said composition as an active therapeutic substance.
  • the process of the invention is particularly useful for formulating [R-(Z)]- ⁇ - (me ⁇ oxyimino)- ⁇ -(l-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride (compound X) with active doses around 5-125 microgramme ( ⁇ g).
  • Compound X and methods for its preparation are disclosed in EP-A-0392803, WO95/31456 and WO93/17018.
  • the compound enhances acetylcholine function via an action at muscarinic receptors within the central nervous system, and is therefore of potential use in the treatment and/or prophylaxis of dementia in mammals.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and compound X at a level of up to 0.1% by weight of drug to carrier, 0% volatile organic solvent and 0% binder.
  • EP-A-0392803 suggests the suitable daily dose for compound X and other compounds disclosed therein as 0.01-5mg/kg. It has been su ⁇ risingly found through administration to human patients that efficacy as a cognition enhancer may be obtained at daily doses below O.Olmg/kg more particularly 0.003mg/kg and below, for example 0.0001-0.003mg/kg, such as 0.00035-0.003mg/kg, 0.0007-0.003mg/kg, 0.0001- 0.0007mg/kg or 0.00035-0.002mg/kg.
  • the present invention provides a method of treatment and/or prophylaxis of dementia, and more particularly a method of enhancing cognition in a patient, which method comprises administering to the patient compound X at a daily dose below O.Olmg/kg, more preferably 0.003mg/kg or less.
  • the invention also relates to the use of compound X in the manufacture of a medicament for the treatment and/or prophylaxis of dementia at a daily dose below O.Olmg/kg, more preferably of 0.003mg/kg or less.
  • the invention further relates to a pharmaceutical composition for ' the treatment and/or prophylaxis of dementia which comprises compound X at a unit dose suitable for admimstration at a daily dose below O.Olmg kg, more preferably of 0.003mg kg or less, and a pharmaceutically acceptable carrier.
  • Suitable unit doses to achieve such daily doses are 5, 12.5, 25, 50 or 75 ⁇ g, administered twice daily and, in the case of 50 ⁇ g, once daily.
  • Such unit doses are calculated on the basis of 50-70kg individuals.
  • the invention extends to the method, use or composition defined above wherein compound X is provided in such unit doses.
  • the invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising compound X of the invention and/or formulated in accordance with the process of the invention, in unit dose form selected from the range 5-125 ⁇ g per unit dose, such as 5, 12.5, 25, 50 or 75 ⁇ g per unit dose and the use of said composition as an active therapeutic substance, in pa ⁇ icular in the treatment and or prophylaxis of dementia.
  • the amount of drug used in the above methods is 50, 33.6, 16.8, 8.4 and 3.3g respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A drug formulation process which comprises admixing carrier particles with a solution of drug in water in a quantity of 1-3 % by weight of solution to total mix and a method of treatment and/or prophylaxis of dementia, which method comprises administering to the patient [R-(Z)]-α-(methoxyimino)-α-(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride at a daily dose below 0.01 mg/kg and pharmaceutical compositions used therein.

Description

PROCESS FOR PREPARING SOLID DOSAGE FORMS OF VERY LOW-DOSE DRUGS
This invention relates to a method of formulating solid dosage forms of drugs and to solid dosage forms produced thereby, in particular solid dosage forms containing low dose of drug. The invention also relates to a method of treatment and/or prophylaxis of dementia and unit dosage forms useful therein.
The usual challenge in manufacturing solid dosage forms of very low-dose drugs, for example with active doses around 5-125 microgramme (μg) (for example 0.004-0.1% by weight of drug to total solid), is to ensure homogeneity. The techmcal problem is how to distribute the drug substance evenly among the large amount of excipient particles.
The simplest way of manufacturing tablets is simply to blend all the ingredients as dry powders and tablet them ("direct compression"). This is rarely successful for low-dose drugs; a common problem being segregation of the powder blend during tabletting. A variation of this method which has been successful for low-dose drugs is known as "trituration", and is sometimes referred to as "ordered mixing" or "interactive mixing".
Very fine particles of the drug are first mixed with a small portion of excipient; the product then mixed with a slighty larger portion of excipient and so on until the desired mix is obtained. This method relies on the fine drug particles adhering electrostatically to the larger excipient ones, thus preventing segregation. The method works with some drugs, but success depends on the surface properties of both drug and excipient, and the method is very laborious. EP0503521 describes the application of this method to steroidal drugs with high binding affinity and low demixing potential for certain excipients.
A preferred alternative method for formulating low dose drugs is known as "wet granulation". The drug is dissolved in water or another solvent, and blended with excipients including a binder, for example povidone, to form a wet mass containing 5-20% by weight of solution to total weight of granulation mix, which is then dried off in a separate step. The binder causes particles of excipient to clump together, and as the mass dries these clumps ("granules") either contain or are coated with the drug. This is effective but cumbersome since the drying step requires special equipment, and generally involves high temperatures which may degrade labile drugs. Also, the use of the binder requires the further inclusion of a disintegrant such as sodium starch glycolate or starch to help the tablet, which is cohesive, to disperse in the stomach.
Fluid bed granulation has been used to achieve content uniformity of low dose (lμg-lOmg) tablets (Thiel et al., J. Pharm. Pharmacol. 1986, 38, 335-343). In this process, the micronised drug is blended as a powder with other excipients, then loaded into a fluid bed granulator, and the powders are agglomerated by spraying on a solution of a binder; drying takes place concomitantly. The process does not require a separate drying step, but it does require the use of micronised drug, and also incorporates a separate blending step prior to granulation. It also requires specialised equipment and precise optimisation ofthe process parameters.
Another process for formulating low dose drugs is known as carrier granulation (Michoel et aL, Pharmaceutical Technology June 1988, 66-84). This functions by spraying a solution of binder such as povidone in water onto relatively large excipient particles such as hydrous lactose and then spraying small dry drug substance particles onto that, thus coating the excipient with drug particles which are stuck on by the binder. The quantity of solution used was 3.3-3.5% by weight of solution to total granulation mix. The method was applied to a formulation containing 4-5% drug by weight This method also requires drying; the drug particle size needs to be very small, which often requires an extra milling step and the very fine drug powder may not flow at all well; and the formula still requires a disintegrant
Dahl et al., Drug Development and Industrial Pharmacy 1990, 16 (12), 1881-1891, describes the preparation of solid capsule formulations using a spray-on liquid drug carrier. The model drug is dissolved in a non- volatile solvent propylene carbonate, and sprayed onto a compressible sugar at a loading of around 0.01% by weight of drug to total solid, to give a final unit dose of 35μg. The solvent being non-volatile, remains in the blend. It is added at around 5% by weight of the total formulation; lower ratios of solvent to solid resulted in decreased ability to disintegrate and dissolve. The resulting, somewhat sticky, powder showed some difficulties in automated encapsulation machines, and would be likely to give significant problems in tabletting.
Yalkowski (US4,489,026) describes a process which involves very slowly spraying a dilute solution of drug in a volatile inert solvent preferably an organic solvent having a boiling point lower than 80°C, onto excipient powder in an open coating pan; a continuous flow of air dries the product during the spraying process. This process was applied to drugs with a unit dose of lOug or less. The spray rate is limited to 1-lOml/min, making the process suitable only for very small batch-sizes (the example quoted prepared 1000 tablets). The weight ratio of solution to carrier used was 15%; also, the use of volatile organic liquids is now regarded as a significant hazard, requiring solvent-recovery processes and explosion-proof equipment
Katdare (US4,898,736) describes a simplified version of this process, suitable for unit doses of 50-1000μg; the drug, dissolved in an easily evaporated solvent such as ethanol, methanol, acetone or tetrahydrofuran, is simply blended with excipients in a ratio of 2.26% or 6.75% and then dried, followed by lubrication and tabletting. This process is in principle suitable for commercial scale manufacture, but does still have the problems associated with the use of volatile organic solvents. According to the present invention there is provided a drug formulation process which comprises admixing carrier particles with a solution of drug in water in a quantity of 1-3% by weight of solution to total mix.
The resulting mixture may be formulated into suitable unit dose presentation, for example by tabletting and optionally film coating the tablets or by encapsulation.
It may be convenient to make the initial drug/carrier mix with a higher drug concentration, and then in a separate step blending that with further carrier, and this may be particularly useful where a range of tablet strengths is required. The separate blending step aids drying by the dilution effect that is, the residual water is distributed through a greater quantity of carrier powder, and by the longer mixing time. The dilution is conveniently in the range 4/1 to 40/1 carrier/concentrate by weight depending upon the processing characteristics of the carrier. A convenient dilution ratio for lactose monohydrate is 10/1.
Where the dilution step is not employed, the solution/mix weight ratio is more preferably up to 2% by weight
The optimum quantity of solution will depend upon the absorbent qualities of the carrier particles, the solubility of the drug and the characteristics of the mixing device, the quantity of solution being chosen so as to allow even distribution of drug while avoiding the need for a heated drying step. The mixing step is preferably carried out in a high shear mixer.
The carrier may be any suitable soluble, directly compressible pharmaceutically acceptable excipient such as anhydrous lactose, lactose monohydrate, mannitol, or an insoluble, directly compressible pharmaceutically acceptable excipient such as microcrystalline cellulose or dicalcium phosphate, preferably a soluble excipient Any drug having a sufficient degree of solubility in water may be formulated by the process of the invention. The concentration of drug in the soluuon is dependent on the unit dose of drug required, the upper limit being dependent on the solubility ofthe drug.
During mixing, the carrier particles are evenly coated with a very thin film of drug solution. Some of the water naturally dries off during the mixing since there is normally a small airflow through the mixer; the remaining amount is so low that drying is not specifically required. If the tablets are film-coated, a degree of further drying may be obtained during the coating process.
The process of the invention has a number of advantages: - it does not require any milling of the drug substance - there is no need for a drying step. This simplifies processing and reduces production costs; heat labile drugs do not suffer at the temperature required for drying; for drugs which are highly potent the omission of the drying step makes it easier to contain dust r improving safety for the factory worker
- the use of volatile organic solvents is avoided
- there is no need to add a binder - there is no need to add a disintegrant when the excipient is a highly soluble one. Optional additives in the final mix include a disintegrant; a range of acidic or alkaline excipients to improve chemical stability of the drug in the formulation such as sodium dihydrogen citrate, preferably included in the initial mix; a lubricant such as magnesium stearate; and a glidant such as colloidal silica. The present invention further provides a pharmaceutical composition comprising a drug formulated in accordance with the process of the invention and the use of said composition as an active therapeutic substance.
The invention additionally provides a pharmaceutical composition comprising a drug, obtainable by the process of the invention and the use of said composition as an active therapeutic substance.
The process of the invention is particularly useful for formulating [R-(Z)]-α- (meΛoxyimino)-α-(l-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride (compound X) with active doses around 5-125 microgramme (μg). Compound X and methods for its preparation are disclosed in EP-A-0392803, WO95/31456 and WO93/17018. The compound enhances acetylcholine function via an action at muscarinic receptors within the central nervous system, and is therefore of potential use in the treatment and/or prophylaxis of dementia in mammals.
In particular the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and compound X at a level of up to 0.1% by weight of drug to carrier, 0% volatile organic solvent and 0% binder.
EP-A-0392803 suggests the suitable daily dose for compound X and other compounds disclosed therein as 0.01-5mg/kg. It has been suφrisingly found through administration to human patients that efficacy as a cognition enhancer may be obtained at daily doses below O.Olmg/kg more particularly 0.003mg/kg and below, for example 0.0001-0.003mg/kg, such as 0.00035-0.003mg/kg, 0.0007-0.003mg/kg, 0.0001- 0.0007mg/kg or 0.00035-0.002mg/kg.
Accordingly the present invention provides a method of treatment and/or prophylaxis of dementia, and more particularly a method of enhancing cognition in a patient, which method comprises administering to the patient compound X at a daily dose below O.Olmg/kg, more preferably 0.003mg/kg or less. The invention also relates to the use of compound X in the manufacture of a medicament for the treatment and/or prophylaxis of dementia at a daily dose below O.Olmg/kg, more preferably of 0.003mg/kg or less. The invention further relates to a pharmaceutical composition for' the treatment and/or prophylaxis of dementia which comprises compound X at a unit dose suitable for admimstration at a daily dose below O.Olmg kg, more preferably of 0.003mg kg or less, and a pharmaceutically acceptable carrier. Suitable unit doses to achieve such daily doses are 5, 12.5, 25, 50 or 75μg, administered twice daily and, in the case of 50μg, once daily. Such unit doses are calculated on the basis of 50-70kg individuals. The invention extends to the method, use or composition defined above wherein compound X is provided in such unit doses. The invention further provides a pharmaceutical composition comprising compound X of the invention and/or formulated in accordance with the process of the invention, in unit dose form selected from the range 5-125μg per unit dose, such as 5, 12.5, 25, 50 or 75μg per unit dose and the use of said composition as an active therapeutic substance, in paπicular in the treatment and or prophylaxis of dementia.
EXAMPLE
Formulation of compound X
To make 100kg of blend for tabletting or encapsulation, at lOOug drug per 150mg excipient - dissolve 67g drug in lliter of water (i.e. 1% of water (1.067% of solution) on a weight basis)
- slowly add this to 100kg of a "direct compression" grade of lactose monohydrate in a high-shear mixer-granulator
- blend with 0.25kg lubricant (Magnesium Stearate) and 0J5kg Glidant (Colloidal Silica)
- tablet
- filmcoat (optional)
To make 100kg of blend for tabletting or encapsulation, at lOOug drug per 150mg excipient, by way of a concentrate:
- dissolve 67g drug in 0J liter of water
- slowly add this to 9.8kg of a "direct compression" grade of lactose monohydrate and 0.2kg of acidifying agent (Sodium Dihydrogen Citrate) in a high-shear mixer- granulator, followed by a further 0J liter of water to rinse the containers used, while mixing vigorously with a chopper speed of around 1500rpm and then raising the speed to around 3000rpm, for 10-20 minutes total mixing time (i.e. a total of 2% of water (2.67% of solution) is added on a weight basis relative to the amount of concentrate) -sieve the resulting concentrate into a tumble-blender
- blend with 88kg further lactose and 1.8kg Sodium Dihydrogen Citrate, then blend in 0J5kg Glidant (Colloidal Silica) and 0.25kg lubricant (Magnesium Stearate)
- tablet - filmcoat (optional)
To make unit doses of 75, 50, 25, 12.5 and 5μg in 150mg excipient, the amount of drug used in the above methods is 50, 33.6, 16.8, 8.4 and 3.3g respectively.

Claims

I. A drug formulation process which comprises admixing carrier particles with a solution of drug in water in a quantity of 1-3% by weight of solution to total mix.
2. A process according to claim 1 wherein the carrier is a soluble or an insoluble directly compressible pharmaceutically acceptable excipient
3. A process according to claim 2 wherein the carrier is a soluble excipient selected from anhydrous lactose, lactose monohydrate and mannitol.
4. A process according to claim 3 wherein the mixture further comprises an acidic or alkaline excipient to improve chemical stability of the drug in the formulation.
5. A process according to any preceding claim which further comprises blending the mixture with further carrier and/or one or more additives selected from a disintegrant; an acidic or alkaline excipient to improve chemical stability of the dmg in the formulation, a lubricant and a glidant
6. A process according to claim 5 wherein the mix is blended with further carrier in a weight ratio of 1/4 to 1/40.
7. A process according to any preceding claim wherein the mixture is formulated into a unit dose presentation.
8. A process according to any preceding claim for formulating [R-(Z)]-α- (methoxyimino)-α-(l-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride.
9. A pharmaceutical composition comprising a drug, obtainable by the process of any preceding claim.
10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and [R-(Z)]-α-(methoxyimino)-α-( 1 -azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride at a level of up to 0.1% by weight of drug to carrier, 0% volatile organic solvent and 0% binder.
II. A composition according to claim 10 wherein the carrier is a soluble or an insoluble directly compressible pharmaceutically acceptable excipient
12. A composition according to claim 11 wherein the carrier is a soluble excipient selected from anhydrous lactose, lactose monohydrate and mannitol.
13. A composition according to any of claims 10 to 12 which also comprises one or more additives selected from a disintegrant; an acidic excipient to improve, chemical stability of the drug in the formulation, a lubricant and a glidant
14. A composition according to claim 13 which comprises lactose monohydrate, sodium dihydrogen citrate, colloidal silica and magnesium stearate.
15. A composition according to any of claims 10 to 14 formulated into a unit dose presentation.
16. A method of treatment and/or prophylaxis of dementia, which method comprises administering to the patient [R-(Z)]-α-(methoxyimino)-α-(l-azabicyclo [2.2.2]oct-3- yl)acetonitrile monohydrochloride at a daily dose below O.Olmg/kg.
17. The use of [R-(Z)]-α-(methoxyimino)-α-(l-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride in the manufacture of a medicament for the treatment and/or prophylaxis of dementia at a daily dose below O.Olmg kg.
18. A pharmaceutical composition for the treatment and or prophylaxis of dementia which comprises [R-(Z)]-α-(methoxyimino)-α-(l-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride at a unit dose suitable for administration at a daily dose below O.Olmg kg, and a pharmaceutically acceptable carrier.
19. A method, use or composition according to claim 16, 17 or 18 wherein the daily dose is 0.003mg/kg or less.
20. A method, use or composition according to claim 19 wherem the daily dose is 0.0001-0.003mg/kg.
21. A method, use or composition according to claim 20 wherein the daily dose is 0.00035-0.003mg/kg.
22. A method, use or composition according to claim 20 wherein the daily dose is 0.0007-0.003mg/kg.
23. A method, use or composition accordmg to claim 20 wherein the daily dose is 0.0001-0.0007mg/kg.
24. A method, use or composition according to claim 20 wherein the daily dose is 0.00035-0.002mg/kg.
25. A method, use or composition according to claim 16, 17 or 18 wherein tiie compound is presented in a unit dose of 5, 12.5, 25, 50 or 75μg, administered twice daily or, in the case of 50μg, once daily.
26. A pharmaceutical composition according to claim 9 as dependent on claim 8 or according to any of claims 10 to 15, in unit dose form selected from the range 5-125μg per unit dose.
27. A pharmaceutical composition according to claim 26 comprising 5, 12.5, 25, 50 or 75μg per unit dose
28. A pharmaceutical composition according to claim 9, according to any of claims 10 to 15 or according to claim 26 or 27 for use as an active therapeutic substance.
29. A pharmaceutical composition according to claim 9 as dependent on claim 8, according to any of claims 10 to 15 or according to claim 26 or 27 for use in the treatment and/or prophylaxis of dementia.
30. A method of treatment and/or prophylaxis of dementia, which method comprises administering to the patient an effective amount of a composition according to claim 29.
31. Use of a pharmaceutical composition according to claim 29 in the manufacture of a medicament for the treatment and/or prophylaxis of dementia.
- Q —
PCT/EP1996/003326 1995-07-29 1996-07-29 Process for preparing solid dosage forms of very low-dose drugs WO1997004750A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AU67384/96A AU716961B2 (en) 1995-07-29 1996-07-29 Process for preparing solid dosage forms of very low-dose drugs
IL14957996A IL149579A0 (en) 1995-07-29 1996-07-29 Process for preparing solid dosage forms of low-dose drugs
MX9800809A MX9800809A (en) 1995-07-29 1996-07-29 Process for preparing solid dosage forms of very low-dose drugs.
SK110-98A SK11098A3 (en) 1995-07-29 1996-07-29 Process for preparing solid dosage forms of very low-dose drugs
EA199800179A EA000740B1 (en) 1995-07-29 1996-07-29 Process for preparing solid dosage forms of very low-dose drugs and a pharmaceutical obtained therein
IL12289796A IL122897A0 (en) 1995-07-29 1996-07-29 Process for preparing solid dosage forms of very low-dose drugs
EA199901055A EA199901055A1 (en) 1995-07-29 1996-07-29 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF DEMENTIA
APAP/P/1998/001170A AP858A (en) 1995-07-29 1996-07-29 Process for preparing solid dosage forms of very low-dose drugs.
NZ315632A NZ315632A (en) 1995-07-29 1996-07-29 Process for preparing solid dosage forms of very low-dose drugs comprising admixing 1-3% by weight of carrier particles with a solution of drug in water
BR9609804A BR9609804A (en) 1995-07-29 1996-07-29 Process for the preparation of solid dosage forms with very low dosage drugs
EP96927621A EP0841902A2 (en) 1995-07-29 1996-07-29 Process for preparing solid dosage forms of very low-dose drugs
JP9507243A JPH11510493A (en) 1995-07-29 1996-07-29 Method of making solid dosage forms of very low dose drugs
NO980384A NO980384L (en) 1995-07-29 1998-01-28 Process for the preparation of solid dosage forms of very low-dose drugs
BG102266A BG102266A (en) 1995-07-29 1998-02-20 Method for the preparation of solid batched forms having very low doses of the medicamentous form

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9515624.6 1995-07-29
GBGB9515624.6A GB9515624D0 (en) 1995-07-29 1995-07-29 Novel process
GBGB9606684.0A GB9606684D0 (en) 1996-03-29 1996-03-29 Novel process
GB9606684.0 1996-03-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09000252 A-371-Of-International 1998-07-08
US09/759,575 Continuation US20010018074A1 (en) 1995-07-29 2001-01-12 Process for preparing solid dosage forms of very low-dose drugs

Publications (2)

Publication Number Publication Date
WO1997004750A2 true WO1997004750A2 (en) 1997-02-13
WO1997004750A3 WO1997004750A3 (en) 1997-03-27

Family

ID=26307485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/003326 WO1997004750A2 (en) 1995-07-29 1996-07-29 Process for preparing solid dosage forms of very low-dose drugs

Country Status (25)

Country Link
EP (1) EP0841902A2 (en)
JP (1) JPH11510493A (en)
KR (1) KR19990035972A (en)
CN (1) CN1196677A (en)
AP (1) AP858A (en)
AR (1) AR004178A1 (en)
AU (1) AU716961B2 (en)
BG (1) BG102266A (en)
BR (1) BR9609804A (en)
CA (1) CA2228048A1 (en)
CZ (1) CZ24798A3 (en)
DZ (1) DZ2077A1 (en)
EA (2) EA000740B1 (en)
HU (1) HUP9900521A3 (en)
IL (1) IL122897A0 (en)
MA (1) MA23953A1 (en)
MX (1) MX9800809A (en)
NO (1) NO980384L (en)
NZ (1) NZ315632A (en)
OA (1) OA10659A (en)
PL (1) PL325242A1 (en)
SK (1) SK11098A3 (en)
TR (1) TR199800156T1 (en)
UY (1) UY24297A1 (en)
WO (1) WO1997004750A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010762A2 (en) * 1996-09-12 1998-03-19 Smithkline Beecham Plc Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride
WO1999045924A1 (en) * 1998-03-11 1999-09-16 Smithkline Beecham Plc Composition
JP2003505402A (en) * 1999-07-26 2003-02-12 ラボラトワール デ プロデュイ エチク エチファルム Low-dose tablets and preparation method
WO2005097076A2 (en) * 2004-04-09 2005-10-20 Smithkline Beecham Corporation Low dose pharmaceutical products
US7867990B2 (en) 2000-12-14 2011-01-11 Ortho-Mcneil Pharmaceutical, Inc. Steroid hormone products and methods for preparing them

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US4898736A (en) * 1988-03-09 1990-02-06 Merck & Co., Inc. Method for tablet preparation
EP0392803A1 (en) * 1989-04-13 1990-10-17 Beecham Group p.l.c. Novel compounds
WO1995017168A1 (en) * 1993-12-21 1995-06-29 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5970614A (en) * 1982-10-14 1984-04-21 Asahi Chem Ind Co Ltd Wet solid pharmaceutical preparation of very small amount of main drug

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US4898736A (en) * 1988-03-09 1990-02-06 Merck & Co., Inc. Method for tablet preparation
EP0392803A1 (en) * 1989-04-13 1990-10-17 Beecham Group p.l.c. Novel compounds
WO1995017168A1 (en) * 1993-12-21 1995-06-29 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 101, no. 8, 20 August 1984 Columbus, Ohio, US; abstract no. 60165, XP002024576 & JP 59 070 614 A (ASAHI) 21 April 1984 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010762A2 (en) * 1996-09-12 1998-03-19 Smithkline Beecham Plc Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride
WO1998010762A3 (en) * 1996-09-12 1998-06-04 Smithkline Beecham Plc Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride
WO1999045924A1 (en) * 1998-03-11 1999-09-16 Smithkline Beecham Plc Composition
US6451343B1 (en) 1998-03-11 2002-09-17 Smithkline Beecham Corporation Composition for treating dementia and Alzheimer's disease
JP2003505402A (en) * 1999-07-26 2003-02-12 ラボラトワール デ プロデュイ エチク エチファルム Low-dose tablets and preparation method
BG65535B1 (en) * 1999-07-26 2008-11-28 Laboratoires Des Produits Ethiques Ethypharm S.A. Low-dose tablets and preparation method
US7867990B2 (en) 2000-12-14 2011-01-11 Ortho-Mcneil Pharmaceutical, Inc. Steroid hormone products and methods for preparing them
WO2005097076A2 (en) * 2004-04-09 2005-10-20 Smithkline Beecham Corporation Low dose pharmaceutical products
WO2005097076A3 (en) * 2004-04-09 2006-01-05 Smithkline Beecham Corp Low dose pharmaceutical products

Also Published As

Publication number Publication date
HUP9900521A3 (en) 2001-04-28
AP858A (en) 2000-07-12
CZ24798A3 (en) 1998-06-17
MX9800809A (en) 1998-04-30
AR004178A1 (en) 1998-11-04
EA199901055A1 (en) 2000-06-26
NZ315632A (en) 1999-11-29
KR19990035972A (en) 1999-05-25
DZ2077A1 (en) 2002-07-22
EA000740B1 (en) 2000-02-28
AP9801170A0 (en) 1998-01-31
AU6738496A (en) 1997-02-26
MA23953A1 (en) 1997-04-01
SK11098A3 (en) 1998-07-08
NO980384L (en) 1998-03-26
AU716961B2 (en) 2000-03-09
BG102266A (en) 1998-10-30
OA10659A (en) 2002-09-18
CA2228048A1 (en) 1997-02-13
UY24297A1 (en) 1997-01-23
EP0841902A2 (en) 1998-05-20
JPH11510493A (en) 1999-09-14
EA199800179A1 (en) 1998-10-29
TR199800156T1 (en) 1998-04-21
HUP9900521A2 (en) 1999-06-28
WO1997004750A3 (en) 1997-03-27
CN1196677A (en) 1998-10-21
IL122897A0 (en) 1998-08-16
NO980384D0 (en) 1998-01-28
BR9609804A (en) 1999-07-06
PL325242A1 (en) 1998-07-06

Similar Documents

Publication Publication Date Title
JP4868695B2 (en) Oral preparation with good disintegration
JPH0122245B2 (en)
US20030129246A1 (en) Process for preparing solid dosage forms of very low-dose drugs
EP0862421B1 (en) Prompt-release pharmaceutical compositions
AU3033299A (en) Composition
CZ20798A3 (en) Process for preparing taste corrected preparations of quinolone anti-bacterially active preparations
TWI426913B (en) A fine grain agent having improved water-suspensibility
AP858A (en) Process for preparing solid dosage forms of very low-dose drugs.
AU759869B2 (en) Pharmaceutical formulations
MXPA98000809A (en) Procedure to prepare forms of solid doses of very low dose of farm
US8062664B2 (en) Process for preparing formulations of lipid-regulating drugs
SK50132006A3 (en) Fluconazole capsules with improved release
KR102363727B1 (en) Composition for preparing solid formulation containing pranlukast having enhanced bioavailability and production method thereof
AU611740B2 (en) Pharmaceutical composition and process for its preparation
AU751607B2 (en) Method of treatment of dementia
CZ2002179A3 (en) Tablets containing low dosage of active substance, preparation, and process for preparing such tablet
CA2275626C (en) Homogeneous preformulations containing high concentrations of steroids, for producing low-dose solid and semi-solid pharmaceutical preparations
KR20190007896A (en) Orally disintegrating tablet comprising solifenacin or its pharmaceutically acceptable salts, and preparing method thereof
JP2000239185A (en) Pharmaceutical composition
JP2002138034A (en) Bitter taste masked chewable tablet and preparation method of the same
JPH08325142A (en) Preparation containing iodoisopropamide
KR870001374B1 (en) Process for preparing powder medicine products for oral and nasal
US20060177512A1 (en) Process for preparing formulations of lipid-regulating drugs
SK15612000A3 (en) Peroral tablets with controlled release of pharmaceutically acceptable metoprolol salts and method for the preparation thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96197054.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 315632

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1199800050

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 1996927621

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019980700633

Country of ref document: KR

Ref document number: 98-00115

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 11098

Country of ref document: SK

Ref document number: PV1998-247

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2228048

Country of ref document: CA

Ref document number: 2228048

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1997 507243

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/000809

Country of ref document: MX

Ref document number: 1998/00156

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 199800179

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1996927621

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1998-247

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980700633

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 149579

Country of ref document: IL

WWW Wipo information: withdrawn in national office

Ref document number: 1996927621

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-247

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1019980700633

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载